Effects of Triazole Antifungal Agents on the Plasma Concentration and Dosage of Cyclosporin in Patients with Aplastic Anaemia

Table 4

Laboratory safety data in aplastic anaemia patients without triazole antifungal agent co-medication and after triazole antifungal agent co-medication.

	CsA monotherapy	With azole co-medication
Patients with POS
ALT (IU/L)	106.67 ± 90.48	92.39 ± 96.74	0.780
AST (IU/L)	58.04 ± 35.19	59.55 ± 55.74	0.953
TBIL (μmol/L)	19.01 ± 10.96	25.63 ± 16.93	0.413
Creatinine (μmol/L)	70.57 ± 39.80	69.59 ± 31.29	0.960
Urea (mmol/L)	7.64 ± 3.99	7.53 ± 3.85	0.957
Patients with FCZ
ALT (IU/L)	18.74 ± 10.26	17.06 ± 9.78	0.616
AST (IU/L)	14.88 ± 5.93	13.74 ± 4.69	0.527
TBIL (μmol/L)	24.05 ± 17.81	27.60 ± 17.60	0.552
Creatinine (μmol/L)	62.59 ± 22.50	68.75 ± 30.99	0.516
Urea (mmol/L)	6.31 ± 2.82	6.91 ± 2.33	0.525

is the comparison of biochemical indexes of patients before and after co-administered with triazole antifungal agents.